https://doi.org/10.55788/6afcd40d
Men and women with AF have shown different responses to therapies and rates of cardiovascular complications [1]. The EAST-AFNET 4 trial (NCT01288352) demonstrated significant clinical benefits of early rhythm-control therapy for the included patients with AF (46% women) [2]. In the current pre-specified analysis of this trial, Prof. Isabelle van Gelder (University Medical Center Groningen, Netherlands) assessed the interaction effect of early rhythm-control therapy and sex and investigated sex-specific differences in clinical presentation [3].
Patients with early AF (≤12 months) who were >75 years of age, had a previous transient ischemic attack or stroke, or had at least 1 relevant comorbidity were eligible for this analysis (n=2,789). These patients were randomised to early rhythm-control therapy (i.e. anti-arrhythmic drug or ablation) or usual care. The primary efficacy outcomes were a composite of cardiovascular events and nights spent in hospital. The primary safety outcome was a composite of death, stroke, and rhythm control-related serious adverse events (AEs).
At baseline, a higher percentage of women displayed sinus rhythm compared with men (58% vs 51%; P<0.001), whereas men were more frequently asymptomatic (36% vs 25%; P<0.001). In addition, chronic kidney disease (stage 3 or 4) was more common in women (15% vs 11%; P=0.001) and women had a higher mean CHA2DS2-VASc score at baseline than men (3.73 vs 3.02; P<0.001). In contrast, heart failure (33% vs 23%), diabetes (28% vs 21%), and severe coronary artery disease (24% vs 9.6%) were more frequently reported in men than in women (P<0.001). These results show that the clinical characteristics of men and women with AF are different.
After a median follow-up time of 5.1 years, the composite outcome of cardiovascular events favoured early rhythm-control therapy over usual care significantly in women (HR 0.72; 95% CI 0.55–0.93) and numerically in men (HR 0.83; 95% CI 0.67–1.03). The treatment effect of early rhythm-control therapy did not show a significant interaction with sex (P=0.408), demonstrating that the benefit of early rhythm-control therapy is similar in women and men. The mean nights spent in hospital per year were also similar for women (1.4 days) and men (1.3 days).
The primary safety outcome showed similar event rates for women and men on early rhythm-control therapy (15.8% vs 17.2%). Notably, after 2 years of early rhythm control therapy, women displayed numerically higher rates of sinus rhythm than men (84.6% vs 80.0%), whereas men were more frequently asymptomatic (78.2% vs 69.4%).
As discussant of this study, Prof. Barbara Casadei (University of Oxford, UK) concluded: “This study shows that when we follow the guidelines and detect patients early, we can obtain good results with anti-arrhythmic therapy. However, more work needs to be done to assess the different components of early rhythm control therapy, ablation, and antiarrhythmic drugs in men and women with AF.”
- Westerman S & Wenger N. Curr Cardiol Rev. 2019;15(2):136–144.
- Kirchhof P, et al. N Engl J Med 2020;383:1305–1316.
- Van Gelder IC, et al. Sex Differences in Early Rhythm Control Therapy in Patients with Atrial Fibrillation: data from the EAST trial. Late-breaking science 2, EHRA 2022, 3–5 April, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Progression in remote app-based monitoring of atrial fibrillation Next Article
Sex differences revealed in AF determinants and AF progression »
« Progression in remote app-based monitoring of atrial fibrillation Next Article
Sex differences revealed in AF determinants and AF progression »
Table of Contents: EHRA 2022
Featured articles
Letter from the Editor
Diagnostics and Prevention
Cardiac magnetic resonance imaging improves prediction of post-MI sudden cardiac death
AI model accurately predicts sudden cardiac death in overall population
AI model accurately discriminates between arrhythmias
Impact of AF screening on stroke prevention influenced by systolic blood pressure
Developments in Devices
Conduction system pacing potential alternative for biventricular pacing in heart failure
Left bundle branch area pacing is a feasible technique for HF and bradyarrhythmia
Focus on the efficacy of cardiac resynchronisation therapy in HF plus concomitant AF
RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure
Insertable cardiac monitors effective for AF detection in cryptogenic stroke
Updates on Ablation
First results of the POWER FAST III trial
Real-world safety results on pulsed-field ablation with pentaspline catheter
VANISH: Ablation reduces shock burden compared with anti-arrhythmic drug in ventricular tachycardia
Low AF recurrence rates after PVI using pulsed-field ablation
Pulsed-field ablation reduces neurocardiac damage versus cryoballoon ablation
Ultrasound-guided femoral venipuncture reduces complications in catheter ablation
News on Atrial Fibrillation
Sex differences revealed in AF determinants and AF progression
Early rhythm-control therapy efficacious in men and women with AF
Progression in remote app-based monitoring of atrial fibrillation
Other Topics
Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy